Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
收藏数据链接：
官方服务：
资源简介：
ORR, DCR, and BOR in patients treated with cobolimab 100, 300, or 900 mg plus dostarlimab.
创建时间：
2025-08-14
